Skip to Main Content

Paper Details

Real-World Outcomes of Patients with Metastatic Non-Small Cell Lung Cancer Treated with Programmed Cell Death Protein 1 Inhibitors in the Year Following U.S. Regulatory Approval.
Oncologist
55
2019

Datasets

Release 1.2